Biosimilars uptake and patient safety

Biosimilar engineers and their outsourcing accomplices must know about the picked nation's administrative scene, and have broad information of any current biosimilar endorsement pathway and the most recent administrative organization rules. Furnishing administrative experts with endorsements of investigation (CoA) for a U.S.- advertised comparator could challenge. As opposed to European practice, U.S. makers tend not to make CoAs accessible to parties required in the production network or bolster the improvement of a contender by discharging CoAs for clumps acquired for clinical trials. Giving family proclamations to the reference item more often than not is acknowledged as an option.

  • Case studies of biosimilar approvals/rejections
  • Challenges in clinical development
  • Analytical Development and Quality Control

Related Conference of Biosimilars uptake and patient safety

August 20-21, 2018

12th Asian Biologics and Biosimilars Congress

Tokyo, Japan
August 29-30, 2018 |

International Conference and Exhibition on Drug Safety & Pharmacovigilance

Park Inn By Radisson, Toronto, Canada
October 18-20, 2018

18th World Pharma Congress

Warsaw, Poland
November 14-15, 2018

13th International Conference on Biosimilars and Biologics

Lisbon, Portugal
September 18-19, 2018

6 th European Biopharma Congress

Amsterdam, Netherlands

Biosimilars uptake and patient safety Conference Speakers

Recommended Sessions

Related Journals

Are you interested in